Robert Orlowski, Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared on X:
“Myeloma Paper of the Day:
Biparatopic targeting of CD38 using CD38-specific trimeric antibody recruiters improves cytotoxicity against myeloma, including the rare cases in which daratumumab fails to bind due to CD38 mutations.”
Title: Biparatopic targeting of CD38 using CD38-specific trimeric antibody recruiters improves cytotoxicity against multiple myeloma
Authors: Henry Risch, Anna Josephine Gebhardt, Niklas Hagen, Anya Duttmann, Marten Dannenberg, Sofie Kämereit, Ricardo Ahrens, Maximilian Al-Bazaz, Kristoffer Riecken, Boris Fehse, Katja Weisel, Peter Bannas, Friedrich Koch-Nolte, Luca Julius Pape, Julia Hambach
You can read the full article on Frontiers in Immunology.
You can find other articles featuring Robert Orlowski on OncoDaily.
